Earnings Call · Q3 FY2025·2026-02-06

Q3 25EPS +22.58%·Rev n/aQ1 25EPS -8.70%·Rev n/aQ4 24EPS -10.31%·Rev n/aQ3 24EPS +16.67%·Rev n/a⚠ consensus missing

Roivant Sciences Ltd. ROIV

Stephanie Lee Griffin — Investor Relations

Matthew Gline — Chief Executive Officer

Benjamin Zimmer — Chief Medical Officer

+22.1%1d on move date+20.2% vs SPY3d+29.4%5d+26.5%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ROIV calls or request research access.

More ROIV calls Browse calls Request research access